A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.

[1]  Y. Efebera,et al.  Improved accuracy of acute graft-versus-host disease staging among multiple centers. , 2014, Best practice & research. Clinical haematology.

[2]  N. Kröger,et al.  Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation , 2014, Annals of Hematology.

[3]  T. Braun,et al.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. , 2013, The New England journal of medicine.

[4]  M. Aljurf,et al.  The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors. , 2013, Blood.

[5]  H. Deeg,et al.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[7]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  J. Bolaños-Meade,et al.  Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. , 2012, Blood.

[9]  M. Horowitz,et al.  Risk factors for acute GVHD and survival after hematopoietic cell transplantation. , 2012, Blood.

[10]  Thomas M Braun,et al.  Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. , 2011, Blood.

[11]  E. Shpall,et al.  Steroid-Refractory Acute GVHD: Predictors and Outcomes , 2011, Advances in hematology.

[12]  J. Perkins,et al.  Dysglycemia following glucocorticoid therapy for acute graft-versus-host disease adversely affects transplantation outcomes. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. Bolaños-Meade,et al.  Graft-versus-host disease treatment: predictors of survival. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[15]  T. Braun,et al.  Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  M. MacMillan,et al.  The best endpoint for acute GVHD treatment trials. , 2010, Blood.

[17]  C. Fiocchi,et al.  Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis , 2010, Proceedings of the National Academy of Sciences.

[18]  Thomas M Braun,et al.  Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin , 2008, Science Translational Medicine.

[19]  J. Ritz,et al.  Current challenges in chronic graft-versus-host disease. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  T. Braun,et al.  Frequency of CD4 + CD25 hi FOXP3 + Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-Versus-Host Disease. , 2009 .

[21]  S. Bhatia,et al.  Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation , 2009, Cancer.

[22]  R. Storb,et al.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. , 2009, Blood.

[23]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[24]  E. Holler,et al.  Graft-versus-host disease , 2009, The Lancet.

[25]  E. Holler.  Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. , 2007, Best practice & research. Clinical haematology.

[26]  H. Deeg,et al.  How I treat refractory acute GVHD. , 2007, Blood.

[27]  J. Klein,et al.  Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. , 2005, Blood.

[28]  C. A. de Souza,et al.  Infectious complications in patients randomized to receive allogeneic bone marrow or peripheral blood transplantation , 2003, Transplant infectious disease : an official journal of the Transplantation Society.

[29]  S. Takasawa,et al.  Increased Expression of HIP/PAP and Regenerating Gene III in Human Inflammatory Bowel Disease and a Murine Bacterial Reconstitution Model , 2003, Inflammatory bowel diseases.

[30]  M. V. D. van den Brink,et al.  Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. , 2003, Blood.

[31]  M. Zahurak,et al.  Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  Rachel L. Mistur,et al.  Graft-Versus-Host Disease , 2016 .

[33]  G. Hill,et al.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.

[34]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[35]  M. Johnson,et al.  Graft-versus-host reactions in dermatology. , 1998, Journal of the American Academy of Dermatology.

[36]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[37]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[38]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[39]  H. Akaike.  A new look at the statistical model identification , 1974 .